Amir Tahami
Amir Tahami has been leading diverse global and local activities dedicated to defining, developing, and delivering scientific evidence of clinical and economic value to ensure patients, payers, and providers have the best possible information for healthcare decision-making and health policy about innovative medicines. During his career, he has developed, launched, and commercialized over twenty medicines in various therapeutic areas, including respiratory, cardiovascular, diabetes, infectious diseases (HIV and HCV), immunology, oncology, and neurology including the industry-leading medicines in immuno-oncology鈥擸ERVOY庐 and OPDIVO庐鈥攁nd the blockbusters鈥擭ASONEX庐, REMICADE庐, SIMPONI庐, and ELIQUIS庐.
听
Research areas span a range of topics in Epidemiology and Biostatistics and are driven by an interest in developing statistically sound solutions to real-world problems, particularly in the design and application of Pharmacoepidemiology, Pharmacoeconomics, and Health Services Research.
Biostatistics, Clinical Epidemiology, Epidemiologic Methods, Health and Social Policy, Health Services Research, Health Technology Assessment, Pharmacoepidemiology, Pharmacoeconomics.